Product Name: TRKB (699-705) pY702
Product Number: PE-04AQE95
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: TRKB (699-705) pY702

Product Use: Services as a blocking peptide for use with the TrkB-pY702 rabbit polyclonal antibody (Cat. No.: AB-PK839) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y702 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: RDV-pY-STD

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1108.05 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: TRKB - pY702 phosphosite-specific antibody (Cat. No.: AB-PK839)

Scientific Background: TrkB is a receptor protein-tyrosine kinase that is a member of the TK group of protein kinases in the Trk family. This kinase shows high variability in human tissue distribution with the highest levels detected in brain, ovary, pancreas, pituitary, spinal cord, thyroid and trachea. TrkB is activated by binding BDNF, NT-3, NT-4 or NT-5, which induce dimerization and autophosphorylation. Phosphorylation at Y516 increases phosphotransferase activity and induces interaction with PLCg1. TrkB activation stimulates signalling throught the MAPK pathway. Signalling through TrkB leads to cell differentiation. Mutations in the TrkB gene have been associated with obesity and mood disorders. TrkB has also been linked with the development of colon and lung cancers, neuroblastomas and pilocytic astrocytomas, which are benign tumours of the brain or spinal cord that grow slowly.